Status:

RECRUITING

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

Lead Sponsor:

Insel Gruppe AG, University Hospital Bern

Conditions:

Ischemic Stroke

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Brief Summary

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading ...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • Written informed consent (by patient, next of kin or legally authorised representative)
  • Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation
  • Acute (≤7 days), symptomatic ischemic stroke

Exclusion

  • Life expectancy \<1 year according to the opinion of the investigator
  • Patient is unlikely to attend follow-up visits

Key Trial Info

Start Date :

November 4 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2028

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT06954610

Start Date

November 4 2025

End Date

June 30 2028

Last Update

November 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Inselspital Bern

Bern, Switzerland, 3010

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation | DecenTrialz